Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$4.4 - $6.74 $7,414 - $11,356
-1,685 Reduced 13.7%
10,618 $70,000
Q3 2023

Nov 14, 2023

BUY
$3.47 - $4.61 $3,254 - $4,324
938 Added 8.25%
12,303 $44,000
Q1 2023

May 15, 2023

SELL
$3.01 - $3.87 $602 - $774
-200 Reduced 1.73%
11,365 $37,000
Q4 2022

Jun 14, 2023

BUY
$2.47 - $3.88 $494 - $776
200 Added 1.76%
11,565 $44.9 Million
Q4 2022

Mar 30, 2023

BUY
$2.47 - $3.88 $10,875 - $17,083
4,403 Added 61.48%
11,565 $44,000
Q4 2022

Feb 15, 2023

BUY
$2.47 - $3.88 $10,875 - $17,083
4,403 Added 61.48%
11,565 $44,000
Q3 2022

Jun 14, 2023

SELL
$2.03 - $2.86 $8,532 - $12,020
-4,203 Reduced 36.98%
7,162 $17.4 Million
Q3 2022

Mar 30, 2023

SELL
$2.03 - $2.86 $8,611 - $12,132
-4,242 Reduced 37.2%
7,162 $17,000
Q3 2022

Nov 14, 2022

SELL
$2.03 - $2.86 $8,611 - $12,132
-4,242 Reduced 37.2%
7,162 $17,000
Q2 2022

Jun 20, 2023

BUY
$1.43 - $2.2 $55 - $85
39 Added 0.34%
11,404 $22,000
Q2 2022

Mar 30, 2023

SELL
$1.43 - $2.2 $20,979 - $32,276
-14,671 Reduced 56.26%
11,404 $22,000
Q2 2022

Aug 11, 2022

BUY
$1.43 - $2.2 $16,307 - $25,088
11,404 New
11,404 $23,000
Q2 2020

Aug 14, 2020

SELL
$2.42 - $3.29 $63,101 - $85,786
-26,075 Closed
0 $0
Q1 2020

Jul 12, 2023

BUY
$1.5 - $4.59 $22,065 - $67,518
14,710 Added 129.43%
26,075 $75,000
Q1 2020

Mar 30, 2023

BUY
$1.5 - $4.59 $10,425 - $31,900
6,950 Added 36.34%
26,075 $75,000
Q1 2020

May 15, 2020

BUY
$1.5 - $4.59 $39,112 - $119,684
26,075 New
26,075 $75,000
Q4 2019

Feb 14, 2020

SELL
$3.89 - $5.15 $74,396 - $98,493
-19,125 Closed
0 $0
Q3 2019

Jul 12, 2023

BUY
$3.19 - $5.39 $24,754 - $41,826
7,760 Added 68.28%
19,125 $85,000
Q3 2019

Mar 30, 2023

BUY
$3.19 - $5.39 $24,116 - $40,748
7,560 Added 65.37%
19,125 $85,000
Q3 2019

Nov 14, 2019

BUY
$3.19 - $5.39 $61,008 - $103,083
19,125 New
19,125 $85,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.31B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.